Horizon Investments LLC Buys 3,598 Shares of Pfizer Inc. (NYSE:PFE)

Horizon Investments LLC lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 4.4% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 86,200 shares of the biopharmaceutical company’s stock after purchasing an additional 3,598 shares during the quarter. Horizon Investments LLC’s holdings in Pfizer were worth $2,144,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Clarity Asset Management Inc. bought a new position in Pfizer in the 4th quarter worth about $27,000. Gould Capital LLC increased its stake in Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 493 shares during the last quarter. GKV Capital Management Co. Inc. bought a new position in Pfizer in the 1st quarter worth about $27,000. North Capital Inc. bought a new position in Pfizer in the 1st quarter worth about $28,000. Finally, Bayforest Capital Ltd bought a new position in Pfizer in the 1st quarter worth about $28,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Trading Up 0.2%

Shares of PFE stock opened at $25.16 on Friday. The stock has a market capitalization of $143.05 billion, a PE ratio of 13.38, a P/E/G ratio of 0.89 and a beta of 0.52. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $30.43. The business has a 50-day moving average of $24.60 and a 200 day moving average of $24.45. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. Pfizer’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the business posted $0.60 EPS. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be issued a $0.43 dividend. The ex-dividend date is Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 6.8%. Pfizer’s dividend payout ratio (DPR) is 91.49%.

Wall Street Analyst Weigh In

PFE has been the topic of a number of research analyst reports. TD Cowen decreased their target price on Pfizer from $32.00 to $28.00 and set a “hold” rating on the stock in a research note on Tuesday, April 22nd. Citigroup upped their target price on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Jefferies Financial Group upped their target price on Pfizer from $32.00 to $33.00 and gave the stock a “buy” rating in a research note on Wednesday, May 21st. Wolfe Research upped their price objective on Pfizer from $22.00 to $23.00 and gave the stock an “underperform” rating in a report on Wednesday, April 30th. Finally, Berenberg Bank cut their price objective on Pfizer from $28.00 to $25.00 and set a “hold” rating for the company in a report on Thursday, May 29th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating, five have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.